Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance

ABSTRACT: We conducted single-cell RNA sequencing using the 10x Genomics Chromium Next-GEM Flex protocol to investigate the mechanism of action behind the improved therapeutic efficacy of anti-CTLA4 seen when combined with FcgrII blockade. Our goal was to understand the mechanism of action of the combination of anti-CTLA4 and anti-FcgrII in comparison to anti-CTLA4 single treatment. These studies provide new insights and role of FcgrII blockade as therapeutic target in cancer.

ORGANISM(S): Mus musculus

PROVIDER: GSE335831 | GEO | 2026/07/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Leveraging TNFR2 for antitumour immunity: Treg depletion and myeloid reprogramming versus T cell costimulation

Project description:We conducted single-cell RNA sequencing using the 10x Genomics Chromium Next-GEM Flex protocol to investigate the mechanism of action of two TNFR2-targeting antibodies—one ligand-blocking and the other agonistic. Our goal was to assess their anti-cancer potential in comparison to established immune checkpoint inhibitors, anti-PD1 and anti-CTLA4. These studies provide new insights and role of TNFR2 as a therapeutic target in cancer.

2026-07-09 | GSE330958 | GEO

Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance

Project description:Tailored FcγR blockade enhances immune checkpoint therapy and overcomes resistance

| PRJNA1479667 | ENA

XIAP-coordinated PKC signaling overcomes immunotherapy resistance via immunogenic rewiring to empower therapeutic rechallenge [scRNA-seq]

Project description:Immune-checkpoint blockade (ICB) against PD-1/PD-L1 has transformed cancer care, yet primary and acquired resistance limit its reach. By profiling substrate-based protein kinase C (PKC) activity, rather than pan-PKC expression, we uncover a superior biomarker predicting survival and anti-PD-1 responsiveness in non-small cell lung cancer (NSCLC). Critically, pharmacological pan-PKC inhibition overcomes anti-PD-1 resistance across diverse preclinical models through a coordinated immunologic program. Specifically, PKC blockade triggers Caspase-3/GSDME-dependent immunogenic cell death (ICD) with ATP/HMGB1 release. It concurrently reprograms the tumor microenvironment (TME) by enriching CD8+ T cells and regulatory T cells (Tregs) in a CCR5-dependent manner, while inducing tumor-intrinsic PD-L1 degradation to sustain CD8+ T cell function. Mechanistically, targeting PKC destabilizes XIAP, whose degradation not only unleashes caspase-mediated ICD and PD-L1 degradation but also licenses CCL4 secretion for CCR5-centric TME rewiring. Importantly, PKC blockade synergizes exclusively with anti-CTLA4 by selectively depleting intratumoral Tregs, providing a rational rechallenge regimen for anti-PD-1-refractory malignancies. Our findings establish PKC activity as a crucial biomarker and validate PKC inhibition as a translatable strategy to dismantle ICB resistance.

2026-05-16 | GSE303943 | GEO

XIAP-coordinated PKC signaling overcomes immunotherapy resistance via immunogenic rewiring to empower therapeutic rechallenge [RNA-Seq]

2026-05-16 | GSE303940 | GEO

Early Changes In B Cell Subsets Predict Risk Of Autoimmunity Following Combination Immune Checkpoint Blockade

Project description:We report changes in B cells in patients treated with combination immune checkpoint blockade (CCB; anti-CTLA4 and anti-PD1)

2017-11-29 | GSE104600 | GEO

Efficacious anti-CTLA-4 antibodies drive myeloid activation and TME reprograming through FcγR engagement and Type-I interferon signaling

Project description:Despite the clinical success of checkpoints inhibitors, a significant gap still exists in our understanding of their in vivo mechanism of action, thus limiting the rational development of next generation agents. Amongst these, anti-CTLA-4 antibodies were originally developed to block inhibitory signals into activated effector T cells. However, several recent studies have demonstrated that depletion of regulatory T cells expressing high levels of CTLA-4 is critical to anti-CTLA-4 anti-tumor activity. Whereas the mechanism of action remains controversial, the emerging data support clinical development of new antibodies with enhanced killing activity. Here, using single-cell RNA sequencing in in vivo and in vitro mouse models, we sought to dissect the impact of anti-CTLA-4 blocking, Treg depleting, and FcR engaging activity on the immune responses within tumors. We observed a rapid remodeling of the innate immune landscape as early as 24-hours post-treatment. Immune remodeling was driven mainly by FcγR-engagement, and not by Treg depletion or CTLA-4 blockade, and included reduction of suppressive macrophages and activation of type-I interferon signaling. Our findings indicate that FcγR engagement and innate immune remodeling are involved in successful anti-CTLA-4 treatment, supporting further development of optimized immunotherapy agents with these features.

2022-08-11 | GSE186484 | GEO

ProCTLA-4 in anti-tumor immunity

Project description:We developed a prodrug of the anti-CTLA4 antibody, named ProCTLA-4. ProCTLA-4 elicits anti-tumor immune responses with reduced toxicity compared to current CTLA4 blockade therapies. Moreover, compared to currently used Probody Therapeutics targeting CTLA-4, ProCTLA-4 offers significant advantages for enhanced efficacy. Thus, our design establishes an alternative paradigm for antibody therapeutics that enables reduction of irAEs while simultaneously increasing therapeutic efficacy.

2025-08-20 | GSE305582 | GEO

Single cell gene expression, immune receptor and cell surface marker expression profiling of Spike-specfic splenic T and B cells of immunized mice

Project description:Spike-specific T and B cells from splenocytes of immunized mice were profiled with 10x sequencing for gene expression (Chromium Next Automated GEM 5’ v2 kit), cell surface marker (Chromium Automated 5’ Feature Barcode kit) and immune receptor (Chromium Automated Mouse BCR/TCR Amplification and Library Construction kit)

2023-08-07 | GSE222403 | GEO

Functional characterization of human T cell hyporesponsiveness induced by CTLA4-Ig

Project description:During activation, T cells integrate multiple signals from APCs and cytokine milieu. The blockade of these signals can have clinical benefits as exemplified by CTLA4-Ig, which blocks interaction of B7 co-stimulatory molecules on APCs with CD28 on T cells. Variants of CTLA4-Ig, abatacept and belatacept are FDA approved as immunosuppressive agents in arthritis and transplantation whereas murine studies suggested that CTLA4-Ig can be beneficial in a number of other diseases. However, detailed analysis of human CD4 cell hyporesponsivness induced by CTLA4-Ig has not been performed. Herein, we established a model to study effect of CTLA4-Ig on the activation of human naM-CM-/ve T cells in a human mixed lymphocytes system. Comparison of human CD4 cells activated in the presence or absence of CTLA4-Ig, showed that co-stimulation blockade during TCR activation does not affect NFAT signaling but results in decreased activation of NF-kB and AP-1 transcription factors followed by profound decrease in proliferation and cytokine production. The resulting T cells become hyporesponsive to secondary activation and, although capable of receiving TCR signals, fail to proliferate or produce cytokines, demonstrating properties of anergic cells. However, unlike some models of T cell anergy, these cells did not possess increased levels of TCR signaling inhibitor CBLB. Rather, the CTLA4-Ig induced hyporesponsiveness was associated with an elevated level of p27kip1 cyclin-dependent kinase inhibitor. Time series. Human resting and activated T cell dUTP mRNA-Seq profiles were generated on Illumina HiSeq2500

2015-02-17 | E-GEOD-64712 | biostudies-arrayexpress

Senescence prostate cancer cell promotes resistance to immune checkpoint blockade through ATR activation

Project description:Background: Checkpoint blockade immunotherapy represented by PD-1/PD-L1 or CTLA4 antibody treatment, has been of tremendous success for multiple cancers. Most patients with prostate cancer (PCa) either do not respond to CTLA4 immune checkpoint blockade or develop resistance to it, often because of low CTLA4 antigen presentation in cancer cells.

2025-04-02 | GSE234387 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data